Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? (Q46846313)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

title

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

main subject

leukemia

1 reference

based on heuristic

inferred from title

author

Hagop Kantarjian

series ordinal

1

object named as

Hagop Kantarjian

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

Stefan Faderl

series ordinal

6

object named as

Stefan Faderl

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

Srdan Verstovsek

series ordinal

8

object named as

Srdan Verstovsek

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

Susan O'Brien

series ordinal

2

object named as

Susan O'Brien

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

Mary Beth Rios

series ordinal

9

object named as

Mary Beth Rios

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

Guillermo Garcia-Manero

series ordinal

5

object named as

Guillermo Garcia-Manero

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

Jorge Eduardo Cortes

series ordinal

10

object named as

Jorge Cortes

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

Xuelin Huang

series ordinal

4

object named as

Xuelin Huang

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

Jianqin Shan

series ordinal

3

object named as

Jianqin Shan

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

Farhad Ravandi-Kashani

series ordinal

7

object named as

Farhad Ravandi-Kashani

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

language of work or name

English

0 references

publication date

1 February 2008

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

published in

Cancer

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

volume

112

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

page(s)

837-845

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

cites work

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.23238

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.23238

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.23238

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.23238

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.23238

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.23238

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.23238

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.23238

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.23238

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1002/CNCR.23238

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

PubMed publication ID

18085610

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18085610

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/18085610

ResearchGate publication ID

5762370

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46846313&oldid=1744046606"